Lohmann & Rauscher
9
6
6
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Suprasorb®X+PHMB Pro vs Suprasorb®X+PHMB in Treatment of Infected Venous Leg Ulcers
Role: lead
Evaluation of the Comfort Increase Provided by an Additional Foam Pad on a Lumbar Belt and Its Biophysical Impact
Role: collaborator
Post-Marketing Surveillance of Vliwazell® Prowound Dressing
Role: lead
Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® Pad in the Debridement of Wounds
Role: lead
Lomatuell Pro® Versus UrgoTul® in the Management of Acute Wounds
Role: lead
Suprasorb® CNPendo Used for Negative Pressure Therapy in the Oesophagus and Rectum to Support Defect and Wound Healing
Role: lead
Investigation of a New Compression Bandage System Combining Skin Protection, Padding and Compression in One Single Bandage and Comparing to an Existing One-component Bandage.
Role: lead
Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
Role: lead
Post-Market Clinical-Follow-Up Study of Suprasorb® C Collagen Wound Dressing
Role: lead
All 9 trials loaded